JAVLOR

25MG/ML INF CNC SOL 1X2ML I

Maximum ex-factory price/Ex-factory price ? 4578,60 CZK
Legal basis of maximum ex-factory price/ex-factory price ? Maximum ex-factory price set by the law.

Informace o základní úhradě

Permanent core reimbursement of highly innovative medicinal product ? 4375,46 CZK
Permanent maximum reimbursement of highly innovative medicinal product ? 5660,63 CZK
Indication restriction of reimbursement ? Vinflunin je hrazen v monoterapii léčby dospělých pacientů s pokročilým nebo metastazujícím karcinomem přechodného epitelu močového ústrojí stádia TxN1-3M0 nebo TxNxM1 po selhání předchozích režimů léčby obsahujících platinu u pacientů, kteří současně a) mají výkonnostní stav dle ECOG menší nebo rovno 1, b) neprodělali neoadjuvantní nebo adjuvantní chemoterapii, c) nebyli léčeni více než jednou linií chemoterapie. Léčba je hrazena do progrese základního onemocnění.
Prescribing doctor's specialisation ?
Reporting limit ? S: If it is advisable to concentrate the use of a product in specialist facilities under Section 15(10) of the Act in the public interest, the decision shall allocate the "S" symbol to these products. These products may be charged to the health insurer as a separately charged product solely by specialist facilities under an agreement concluded with the health insurer.
Rough price for the final consumer ? 5915,36 CZK
Rough payment for the final consumer (for 1 prescribed package dispensed) ? 254.73 CZK
Eligible extra payment ?
Eligible extra payment for individuals aged 65 and older ?
Medicinal products reimbursed from health insurance contain the amount of the maximum manufacturer´s price or the producer´s notified price for products which are not subjected to the regulation of the maximum manufacturer´s price, the amount of reimbursement from health insurance and the estimated price for the end consumer (pharmacy price).

Back to list